Appears On
Episode Appearances
The Journal. · May 26, 2026
Novo Nordisk's CEO Has a Comeback Plan
“Hired 9 months prior to lead company transformation; 30+ year Novo veteran tasked with modernizing company strategy and regaining market competitiveness”
GLP-1 receptor agonist drug efficacy and clinical trial outcomesWeight loss drug market competition and market share dynamicsPharmaceutical pricing strategy and list-price reductions
View Analysis